Explore 3 Stock Ideas & Industry Insights Download Free Report

Company price
0.0096 USD 0.00 ( 7.87%)
Last update at 2026-11-13T20:50:00Z
VOLUME
13400
Market Cap
6.67M

Momentum Score

…

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements, hemp-based cannabidiol (CBD), and plant based food products in North America. It offers its products under the PlusCBD, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.02
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

CV Sciences Inc is a U.S. company that develops, manufactures and sells hemp-derived cannabidiol (CBD) wellness products through online and retail channels. Long-term growth may be supported by rising consumer acceptance of CBD, potential regulatory clarity and expansion of product lines and distribution. Investors may find the company attractive as a focused consumer-brand operator positioned to benefit if the market normalizes and demand grows.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
13.79M
Revenue Per Share
0.07
Gross Profit TTM
6.75M
Debt / Equity
-
ROE
-58.72%
Net Debt
0.98M
ROCE
-23.96%
Diluted EPS TTM
-0.01

Insight Announcement

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.95M -2.40M 3.10M -8.26M -15.64M
Net income -0.96M -2.39M 3.10M -8.21M -15.55M
Selling general administrative 7.62M 9.24M 9.74M 12.09M 25.88M
Gross profit 6.75M 7.17M 7.08M 5.55M 8.62M
Reconciled depreciation 0.19M 0.33M 0.23M 0.99M 1.15M
Ebit - - - -6.85M -13.41M
Ebitda - - - -5.73M -14.35M
Operating income -0.47M -2.19M 3.36M -6.85M -18.45M
Interest expense 0.52M 0.21M - 1.54M 0.14M
Tax provision 0.01M -0.01M -0.01M -0.05M -0.09M
Net interest income -0.52M -0.21M - -1.54M -0.14M
Income tax expense - - - -0.05M -0.09M
Total revenue 13.79M 15.71M 16.00M 16.20M 20.05M
Total operating expenses 14.26M 17.89M 12.64M 23.05M 38.49M
Cost of revenue 7.04M 8.54M 8.92M 10.65M 11.43M
Total other income expense net 0.04M -0.21M -0.26M 0.13M 2.94M
Net income from continuing ops -0.96M -2.39M 3.10M -8.21M -15.55M
Net income applicable to common shares - - - -10.05M -15.55M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 6.96M 7.93M 9.20M 12.74M 18.07M
Intangible assets 0.08M 0.09M 0.08M 0.25M 1.49M
Other current assets 0.37M 0.37M 0.54M 3.19M 2.15M
Total liab 5.49M 6.13M 6.30M 13.51M 14.52M
Total stockholder equity 1.47M 1.79M 2.90M -0.78M 3.54M
Common stock - - - - 0.01M
Capital stock 0.02M 0.02M 0.02M 0.01M 0.01M
Retained earnings -87.94M -86.98M -84.59M -87.69M -79.47M
Other liab - - - 0.01M 0.06M
Good will 1.01M 0.97M 0.34M - 0.00M
Other assets - - - - 0.68M
Cash 0.28M 0.45M 1.32M 0.61M 1.38M
Total current liabilities 5.00M 6.11M 6.12M 13.31M 14.46M
Net debt 0.98M 0.22M - 0.61M -
Short long term debt 1.26M 0.68M 0.25M 1.22M 0.92M
Property plant equipment - - - 0.85M 1.72M
Total current assets 5.13M 6.24M 7.94M 11.13M 14.19M
Net tangible assets - - - -1.03M 2.06M
Net receivables 0.40M 0.52M 0.43M 0.77M 2.04M
Inventory 4.09M 4.90M 5.66M 6.56M 8.62M
Accounts payable 1.04M 1.93M 2.31M 2.28M 2.62M
Non currrent assets other 0.05M 0.13M 0.30M 0.51M 0.68M
Non current assets total 1.83M 1.69M 1.26M 1.61M 3.88M
Capital lease obligations 0.35M 0.10M 0.19M 0.30M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.03M -0.16M 0.00M -0.04M
Change to liabilities - - - -1.25M 1.64M
Total cashflows from investing activities - - - - -0.04M
Net borrowings 0.43M 0.04M -1.39M 1.04M 0.19M
Total cash from financing activities 0.34M 0.03M -1.39M 1.12M 4.37M
Change to operating activities - - - - 1.04M
Net income -0.96M -2.39M 3.10M -9.13M -15.55M
Change in cash -0.18M -0.86M 0.71M -0.76M -3.15M
Begin period cash flow 0.45M 1.32M 0.61M 1.38M 4.53M
End period cash flow 0.28M 0.45M 1.32M 0.61M 1.38M
Total cash from operating activities -0.41M -0.86M 2.25M -1.89M -7.49M
Issuance of capital stock - - 0.00M 0.70M 4.41M
Depreciation 0.19M 0.33M 0.23M 0.99M 1.15M
Change to inventory 0.83M 0.80M 1.04M 2.06M 0.22M
Change to account receivables 0.12M -0.08M 0.35M 1.06M -0.99M
Other cashflows from financing activities - - - -0.61M -0.23M
Change to netincome - - - 1.14M 4.93M
Capital expenditures 0.11M 0.02M 0.00M 0.00M 0.04M
Change in working capital -0.47M 0.46M 4.00M 3.56M 1.92M
Stock based compensation 0.50M 0.26M 0.22M 1.01M 3.21M
Other non cash items 0.89M 0.50M 0.63M 2.08M -0.30M
Free cash flow -0.52M -0.88M 2.25M -1.89M -7.52M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CVSI
CV Sciences Inc
0.00
7.87%
0.01 - 5.19 0.48 4.55 0.58 1.56
MKKGY
Merck KGaA ADR
0.45
1.38%
33.07 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
2.27
1.38%
167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
0.31
1.47%
21.43 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.15 - 10.66 0.01 1.16 2.94 23.11

Profile*

CV Sciences Inc

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements, hemp-based cannabidiol (CBD), and plant based food products in North America. It offers its products under the PlusCBD, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.

9530 Padgett Street, San Diego, CA, United States, 92126

866 290 2157

42

Name Title Year Born
Mr. Joseph D. Dowling CEO, Sec. & Director 1957
Mr. Joerg Grasser Chief Financial Officer 1975
Mr. Tim Hitchman VP of Operations NA
Mr. Stuart Tomc Sr. VP of Human Nutrition NA
Mr. Jesse Karagianes Sr. VP of Revenue Growth NA
Ms. Alyssa Dunn Operations Mang. NA
Mr. Joseph D. Dowling CEO, Secretary & Director 1957
Mr. Brendan Hawkins Investor Relations NA
Mr. Jesse Karagianes Senior Vice President of Revenue Growth NA
Ms. Alyssa Dunn Operations Manager NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…